Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$805.50 USD

805.50
2,196,548

-0.64 (-0.08%)

Updated Nov 5, 2024 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

Kinjel Shah headshot

Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study

Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results

Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View

Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

Company News for Oct 28, 2020

Companies In The News Are: PFE, LLY, MMM, SHW.

Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down

Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.

Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates

Lilly (LLY) delivered earnings and revenue surprises of -12.50% and -2.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment

Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $143.59, marking a +0.55% move from the previous day.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure

The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.

Sweta Killa headshot

Weekly ETF Roundup: Broad U.S. Equity Tops, Biotech Flops

ETFs overall gathered about $18.5 billion capital last week, bringing year-to-date inflows of $352.6 billion, ahead of the $211.7 billion seen at this same time a year ago.

Lilly to Acquire Private Biotech for Boosting Pain Portfolio

Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.

Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates

J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.

The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK

The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK

FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec

Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.

Sweta Killa headshot

Pandemic Surges, Stimulus Fades: ETF Strategies to Follow

Volatility has once again been playing foul in the stock market due to resurgent COVID-19 infections and fading hopes of additional stimulus. Investors should follow some techniques to minimize volatility in their portfolio.

Mark Vickery headshot

Stocks Down 2nd Straight Day: Prime, Lilly, United Q3 & More

Market indexes closed lower for their second-straight session, following a string of four days in a row higher.

Celldex Initiates Early-Stage Antibody Study for Skin Disorder

Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.

Kinjel Shah headshot

Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?

Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.